A review of secukinumab in psoriasis treatment

被引：12

作者：

Berg, Scott H. ^{[1
]}

Balogh, Esther A. ^{[1
]}

Ghamrawi, Rima, I ^{[1
]}

Feldman, Steven R. ^{[1
,2
,3
,4
]}

机构：

[1] Wake Forest Sch Med, Dept Dermatol, Ctr Dermatol Res, Winston Salem, NC 27101 USA

[2] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC 27101 USA

[3] Wake Forest Sch Med, Dept Social Sci & Hlth Policy, Winston Salem, NC 27101 USA

[4] Univ Southern Denmark, Dept Dermatol, Odense, Denmark

来源：

IMMUNOTHERAPY | 2021年 / 13卷 / 03期

关键词：

biologics; IL-17A; psoriasis; psoriatic arthritis; secukinumab; SEVERE PLAQUE PSORIASIS; QUALITY-OF-LIFE; ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY; DOUBLE-BLIND; PHASE-II; MAINTAINS EFFICACY; CLINICAL-RESPONSE; CONTROLLED-TRIAL; SCALP PSORIASIS; POOLED ANALYSIS;

D O I：

10.2217/imt-2020-0195

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Psoriasis is a systemic immunologic disorder associated with decreased quality of life and numerous co-morbidities, including psoriatic arthritis and cardiovascular disease. Secukinumab, a fully human IgG1 monoclonal antibody, selectively binds IL-17A and is approved by the US FDA and European Medicines Agency for moderate-to-severe plaque psoriasis and psoriatic arthritis. This review examines the efficacy and safety of secukinumab for the treatment of psoriasis using the literature retrieved from the PubMed database. In clinical trials, treatment with secukinumab led to rapid and sustained improvement in Psoriasis Area and Severity Index (PASI) scores, with PASI 90 response rates up to 68.5% at 5 years. Long-term clinical trial and real-world data have established secukinumab as a safe and effective treatment for psoriasis.

引用

页码：201 / 216

页数：16

共 106 条

[1] Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity [J].

Arican, O ;

Aral, M ;

Sasmaz, S ;

Ciragil, P .

MEDIATORS OF INFLAMMATION, 2005, (05) :273-279

[2] Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results [J].

Augustin, M. ;

Dauden, E. ;

Mrowietz, U. ;

Konstantinou, M. P. ;

Gerdes, S. ;

Kingo, K. ;

Szepietowski, J. C. ;

Perrot, J. L. ;

Cuccia, A. ;

Rissler, M. ;

Gathmann, S. ;

Sieder, C. ;

Orsenigo, R. ;

Jagiello, P. ;

Bachhuber, T. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (02) :431-440

[3] Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: the PROSE study population [J].

Augustin, M. ;

Dauden, E. ;

Mrowietz, U. ;

Konstantinou, M. P. ;

Gerdes, S. ;

Rissler, M. ;

Gathmann, S. ;

Sieder, C. ;

Baeumer, D. ;

Orsenigo, R. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (11) :2548-2556

[4] Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies [J].

Augustin, M. ;

Jullien, D. ;

Martin, A. ;

Peralta, C. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (06) :1174-1185

[5] Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial [J].

Augustin, M. ;

Abeysinghe, S. ;

Mallya, U. ;

Qureshi, A. ;

Roskell, N. ;

McBride, D. ;

Papavassillis, C. ;

Gelfand, J. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (04) :645-649

[6] Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY) [J].

Bagel, J. ;

Blauvelt, A. ;

Nia, J. ;

Hashim, P. ;

Patekar, M. ;

de Vera, A. ;

Ahmad, K. ;

Paguet, B. ;

Xia, S. ;

Muscianisi, E. ;

Lebwohl, M. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (01) :135-142

[7] Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results) [J].

Bagel, Jerry ;

Nia, John ;

Hashim, Peter W. ;

Patekar, Manmath ;

de Vera, Ana ;

Hugot, Sophie ;

Sheng, Kuan ;

Xia, Summer ;

Gilloteau, Isabelle ;

Muscianisi, Elisa ;

Blauvelt, Andrew ;

Lebwohl, Mark .

DERMATOLOGY AND THERAPY, 2018, 8 (04) :571-579

[8] The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study [J].

Bagel, Jerry ;

Duffin, Kristina Callis ;

Moore, Angela ;

Ferris, Laura K. ;

Siu, Kimberly ;

Steadman, Jennifer ;

Kianifard, Farid ;

Nyirady, Judit ;

Lebwohl, Mark .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (04) :667-674

[9] Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5years of treatment (SCULPTURE Extension Study) [J].

Bissonnette, R. ;

Luger, T. ;

Thaci, D. ;

Toth, D. ;

Lacombe, A. ;

Xia, S. ;

Mazur, R. ;

Patekar, M. ;

Charef, P. ;

Milutinovic, M. ;

Leonardi, C. ;

Mrowietz, U. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (09) :1507-1514

[10] Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study [J].

Bissonnette, R. ;

Luger, T. ;

Thaci, D. ;

Toth, D. ;

Messina, I. ;

You, R. ;

Guana, A. ;

Fox, T. ;

Papavassilis, C. ;

Gilloteau, I. ;

Mrowietz, U. .

BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (04) :1033-1042

← 1 2 3 4 5 6 7 8 9 10 →